Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · IEX Real-Time Price · USD
3.660
-0.040 (-1.08%)
At close: Jul 19, 2024, 4:30 PM
3.540
-0.120 (-3.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Puma Biotechnology Revenue
Puma Biotechnology had revenue of $226.63M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $43.77M. In the year 2023, Puma Biotechnology had annual revenue of $235.64M with 3.34% growth.
Revenue (ttm)
$226.63M
Revenue Growth
-3.59%
P/S Ratio
0.78
Revenue / Employee
$1,225,016
Employees
185
Market Cap
176.55M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 235.64M | 7.61M | 3.34% |
Dec 31, 2022 | 228.03M | -25.12M | -9.92% |
Dec 31, 2021 | 253.16M | 28.05M | 12.46% |
Dec 31, 2020 | 225.11M | -47.15M | -17.32% |
Dec 31, 2019 | 272.26M | 21.27M | 8.47% |
Dec 31, 2018 | 250.99M | 223.31M | 806.60% |
Dec 31, 2017 | 27.69M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 430.55M |
Innate Pharma | 68.49M |
Metagenomi | 47.26M |
Fennec Pharmaceuticals | 44.95M |
MediWound | 19.85M |
PBYI News
- 3 days ago - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results - Business Wire
- 19 days ago - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Business Wire
- 7 weeks ago - Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) - Business Wire
- 7 weeks ago - Puma Biotechnology to Join Russell 3000 Index - Business Wire
- 2 months ago - Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting - Business Wire
- 2 months ago - Puma Biotechnology Reports First Quarter Financial Results - Business Wire
- 3 months ago - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results - Business Wire